Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 2021

View Archived Issues

Novel series of 5,5-fused bicyclic PRMT5 inhibitors as potential anticancer therapeutics

Phase II results of suvratoxumab to prevent S. aureus ventilator-associated pneumonia

C4 selects CFT-8919 for progression into IND-enabling studies

The University of Pennsylvania describes fibronectin-targeting chimeric antigen receptors

AXL oncogene inhibitors discovered at Jiangsu Chia Tai Tianqing Pharmaceutical Group

Dual GLP-1/GCGR agonists synthesized at Dongguan Hec Biological Medicine Research & Development

Oncobix divulges mutant ALK/mutant EGFR inhibitors

REVOLUTION Medicines patents RAS inhibitors

Beclin-1 implicated in diabetic cardiomyopathy

FDA accepts IND application for LY-3819469

Oncorus announces development plans for its novel synthetic vRNA immunotherapy candidates

Gene signature governs anti-plaque microglia in AD

China NMPA approves CTA for phase IIb trial of AM-006 in Parkinson's disease

Activation of MT2 reduces cardiac I/R injury in prediabetic rats

Topical bevacizumab-800CW is safe for detecting esophageal lesions during NIR-FME

OSE's COVID-19 vaccine CoVepiT enters first-in-human study

DSMB recommends continuation of uniQure's phase I/II trial of AMT-130 in Huntington's disease

New biomarkers found to monitor disease progression in eosinophilic esophagitis

Preclinical data show AdCOVID neutralizes SARS-CoV-2 B.1.351 variant

Cystic Fibrosis Foundation awards support research at Metagenomi and Eloxx

AGT103-T HIV therapeutic enters first-in-human study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...